NASDAQ:BLFS BioLife Solutions (BLFS) Stock Forecast, Price & News $23.37 +0.27 (+1.17%) (As of 01:45 PM ET) Add Compare Share Share Today's Range$22.53▼$23.8750-Day Range$17.19▼$23.3652-Week Range$12.60▼$26.96Volume185,344 shsAverage Volume303,406 shsMarket Capitalization$1.02 billionP/E RatioN/ADividend YieldN/APrice Target$28.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media BioLife Solutions MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside23.2% Upside$28.00 Price TargetShort InterestBearish6.25% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.06Based on 2 Articles This WeekInsider TradingSelling Shares$1.83 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.41) to $0.22 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.77 out of 5 starsMedical Sector1669th out of 1,980 stocksElectromedical Equipment Industry33rd out of 46 stocks 2.5 Analyst's Opinion Consensus RatingBioLife Solutions has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.00, BioLife Solutions has a forecasted upside of 23.2% from its current price of $22.72.Amount of Analyst CoverageBioLife Solutions has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.25% of the float of BioLife Solutions has been sold short.Short Interest Ratio / Days to CoverBioLife Solutions has a short interest ratio ("days to cover") of 8.2.Change versus previous monthShort interest in BioLife Solutions has recently increased by 3.72%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBioLife Solutions does not currently pay a dividend.Dividend GrowthBioLife Solutions does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BLFS. Previous Next 2.8 News and Social Media Coverage News SentimentBioLife Solutions has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for BioLife Solutions this week, compared to 3 articles on an average week.MarketBeat Follows3 people have added BioLife Solutions to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BioLife Solutions insiders have sold 22.01% more of their company's stock than they have bought. Specifically, they have bought $1,501,560.00 in company stock and sold $1,832,097.00 in company stock.Percentage Held by InsidersOnly 3.30% of the stock of BioLife Solutions is held by insiders.Percentage Held by Institutions89.82% of the stock of BioLife Solutions is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BioLife Solutions are expected to grow in the coming year, from ($0.41) to $0.22 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioLife Solutions is -6.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioLife Solutions is -6.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioLife Solutions has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About BioLife Solutions (NASDAQ:BLFS) StockBioLife Solutions, Inc. engages in the development, manufacture and marketing of bio preservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs, generic blood stem cell freezing and cell thawing media products and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1987 and is headquartered in Bothell, WA.Read More Receive BLFS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioLife Solutions and its competitors with MarketBeat's FREE daily newsletter. Email Address BLFS Stock News HeadlinesMay 28, 2023 | americanbankingnews.comBioLife Solutions, Inc. (NASDAQ:BLFS) EVP Sells $221,400.00 in StockMay 26, 2023 | americanbankingnews.comInsider Buying: BioLife Solutions, Inc. (NASDAQ:BLFS) Major Shareholder Acquires 24,973 Shares of StockJune 2, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. May 21, 2023 | americanbankingnews.comBioLife Solutions (NASDAQ:BLFS) Shares Gap Up After Insider Buying ActivityMay 18, 2023 | americanbankingnews.comBioLife Solutions (NASDAQ:BLFS) Now Covered by Analysts at StockNews.comMay 16, 2023 | markets.businessinsider.comBioLife Solutions (BLFS) Gets a Buy from Maxim GroupMay 16, 2023 | americanbankingnews.comBrokers Set Expectations for BioLife Solutions, Inc.'s Q2 2023 Earnings (NASDAQ:BLFS)May 12, 2023 | finance.yahoo.comWe Think BioLife Solutions (NASDAQ:BLFS) Can Easily Afford To Drive Business GrowthJune 2, 2023 | Edge On The Street (Ad)The Real Problem With "Made in America" LithiumPoliticians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple. May 11, 2023 | marketwatch.com8-K: BIOLIFE SOLUTIONS INCMay 11, 2023 | finance.yahoo.comQ1 2023 BioLife Solutions Inc Earnings CallMay 10, 2023 | finance.yahoo.comBioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Misses Revenue EstimatesMay 10, 2023 | finance.yahoo.comBioLife Solutions Reports First Quarter 2023 Financial ResultsMay 9, 2023 | markets.businessinsider.comBiolife Solutions earnings: here's what Wall Street expectsMay 8, 2023 | americanbankingnews.comBioLife Solutions (BLFS) Set to Announce Quarterly Earnings on WednesdayMay 2, 2023 | finance.yahoo.comBioLife Solutions to Provide First Quarter 2023 Financial Results and Business Update on May 10, 2023April 28, 2023 | americanbankingnews.comBioLife Solutions (NASDAQ:BLFS) Upgraded to "Sell" by StockNews.comApril 22, 2023 | americanbankingnews.comBioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew Sells 10,000 Shares of StockApril 16, 2023 | americanbankingnews.comBioLife Solutions (NASDAQ:BLFS) Rating Increased to Sell at StockNews.comApril 13, 2023 | americanbankingnews.comBioLife Solutions, Inc. (NASDAQ:BLFS) CRO Sells $15,443.13 in StockApril 13, 2023 | americanbankingnews.comInsider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) CEO Sells 3,214 Shares of StockApril 13, 2023 | americanbankingnews.comBioLife Solutions, Inc. (NASDAQ:BLFS) CMO Sells $30,946.35 in StockApril 12, 2023 | americanbankingnews.comBioLife Solutions (NASDAQ:BLFS) Stock Price Down 3.9% After Insider SellingApril 12, 2023 | americanbankingnews.comKaren A. Foster Sells 1,101 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) StockApril 12, 2023 | americanbankingnews.comAby J. Mathew Sells 2,093 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) StockApril 3, 2023 | americanbankingnews.comShort Interest in BioLife Solutions, Inc. (NASDAQ:BLFS) Increases By 10.4%April 2, 2023 | americanbankingnews.comInsider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) CMO Sells 521 Shares of StockSee More Headlines BLFS Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BLFS Company Calendar Last Earnings3/16/2023Today6/02/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLFS CUSIPN/A CIK834365 Webwww.biolifesolutions.com Phone(425) 402-1400Fax425-402-1433Employees432Year FoundedN/APrice Target and Rating Average Stock Price Forecast$28.00 High Stock Price Forecast$29.00 Low Stock Price Forecast$27.00 Forecasted Upside/Downside+21.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-139,800,000.00 Net Margins-89.08% Pretax Margin-92.15% Return on Equity-8.20% Return on Assets-6.82% Debt Debt-to-Equity Ratio0.07 Current Ratio2.81 Quick Ratio1.93 Sales & Book Value Annual Sales$161.76 million Price / Sales6.21 Cash FlowN/A Price / Cash FlowN/A Book Value$8.24 per share Price / Book2.80Miscellaneous Outstanding Shares43,460,000Free Float42,022,000Market Cap$1.00 billion OptionableNot Optionable Beta1.84 Key ExecutivesMichael P. RiceChairman & Chief Executive OfficerGeraint PhillipsSenior Vice President-Global OperationsTroy WichtermanChief Financial OfficerAby J. MathewChief Scientific Officer & Executive VPRoderick de GreefDirectorKey CompetitorsOutset MedicalNASDAQ:OMAxoGenNASDAQ:AXGNEdap TmsNASDAQ:EDAPZynexNASDAQ:ZYXITransMedics GroupNASDAQ:TMDXView All CompetitorsInsiders & InstitutionsMacquarie Group Ltd.Bought 12,644 shares on 6/1/2023Ownership: 0.157%Aby J MathewSold 10,000 sharesTotal: $221,400.00 ($22.14/share)Ameriprise Financial Inc.Sold 166,156 shares on 5/22/2023Ownership: 2.218%Casdin Partners Master Fund, LBought 24,973 shares on 5/22/2023Total: $545,909.78 ($21.86/share)JPMorgan Chase & Co.Bought 1,250 shares on 5/18/2023Ownership: 0.933%View All Insider TransactionsView All Institutional Transactions BLFS Stock - Frequently Asked Questions Should I buy or sell BioLife Solutions stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BLFS shares. View BLFS analyst ratings or view top-rated stocks. What is BioLife Solutions' stock price forecast for 2023? 2 analysts have issued 12 month target prices for BioLife Solutions' shares. Their BLFS share price forecasts range from $27.00 to $29.00. On average, they expect the company's stock price to reach $28.00 in the next twelve months. This suggests a possible upside of 21.2% from the stock's current price. View analysts price targets for BLFS or view top-rated stocks among Wall Street analysts. How have BLFS shares performed in 2023? BioLife Solutions' stock was trading at $18.20 at the start of the year. Since then, BLFS stock has increased by 26.9% and is now trading at $23.10. View the best growth stocks for 2023 here. When is BioLife Solutions' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our BLFS earnings forecast. How were BioLife Solutions' earnings last quarter? BioLife Solutions, Inc. (NASDAQ:BLFS) issued its quarterly earnings results on Thursday, March, 16th. The medical equipment provider reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.16) by $0.03. The medical equipment provider had revenue of $44.26 million for the quarter, compared to analyst estimates of $43.34 million. BioLife Solutions had a negative net margin of 89.08% and a negative trailing twelve-month return on equity of 8.20%. What ETFs hold BioLife Solutions' stock? ETFs with the largest weight of BioLife Solutions (NASDAQ:BLFS) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), Principal Healthcare Innovators ETF (BTEC), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC) and Syntax Stratified SmallCap ETF (SSLY).iShares Micro-Cap ETF (IWC), What guidance has BioLife Solutions issued on next quarter's earnings? BioLife Solutions updated its FY 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $188.00 million-$202.00 million, compared to the consensus revenue estimate of $192.70 million. What is Mike Rice's approval rating as BioLife Solutions' CEO? 14 employees have rated BioLife Solutions Chief Executive Officer Mike Rice on Glassdoor.com. Mike Rice has an approval rating of 100% among the company's employees. This puts Mike Rice in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 89.0% of employees surveyed would recommend working at BioLife Solutions to a friend. What other stocks do shareholders of BioLife Solutions own? Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Micron Technology (MU), AbbVie (ABBV), Cara Therapeutics (CARA), Gilead Sciences (GILD), Pfizer (PFE), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Twilio (TWLO) and Verastem (VSTM). What is BioLife Solutions' stock symbol? BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS." Who are BioLife Solutions' major shareholders? BioLife Solutions' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (12.56%), Fred Alger Management LLC (4.46%), State Street Corp (2.54%), Palisade Capital Management LP (2.50%), Ameriprise Financial Inc. (2.22%) and Jennison Associates LLC (2.14%). Insiders that own company stock include Aby J Mathew, Aby J Mathew, Amy Duross, Andrew G Hinson, Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, Joseph C Schick, Karen A Foster, Karen A Foster, Marcus Schulz, Michael Rice, Of The University Of C Regents, Raymond W Cohen, Sarah Aebersold, Thomas Girschweiler, Todd Berard, Troy Wichterman and Walter Villiger. View institutional ownership trends. How do I buy shares of BioLife Solutions? Shares of BLFS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BioLife Solutions' stock price today? One share of BLFS stock can currently be purchased for approximately $23.10. How much money does BioLife Solutions make? BioLife Solutions (NASDAQ:BLFS) has a market capitalization of $1.00 billion and generates $161.76 million in revenue each year. The medical equipment provider earns $-139,800,000.00 in net income (profit) each year or ($3.41) on an earnings per share basis. How many employees does BioLife Solutions have? The company employs 432 workers across the globe. How can I contact BioLife Solutions? BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The official website for the company is www.biolifesolutions.com. The medical equipment provider can be reached via phone at (425) 402-1400, via email at rdegreef@biolifesolutions.com, or via fax at 425-402-1433. This page (NASDAQ:BLFS) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLife Solutions, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.